Evaluation of the anticancer property of a new alpha-methylene-gamma-lactone derivative of phthalimide.
The anticancer property of a new alpha-methylene-gamma-lactone derivative of phthalimide (2, NSC 640168) was evaluated in two murine ascitic tumors namely Ehrlich ascites carcinoma (EAC) and sarcoma-180 (S-180) by in vivo screenings and in a battery of human tumor cell lines by in vitro screening. It was found that the compound has exhibited marginal to moderate in vivo activity in EAC and S-180, respectively, and significant in vitro cytotoxicity in SF-268, a human CNS tumor cell line. The compound, however, has not reached the criteria of significant anti-HIV activity.
Sanyal
U
U
Department of Chemotherapy, Chittaranjan National Cancer Institute, Calcutta, India.
Dutta
S
S
Das
H
H
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D002470:Cell Survival / Q000187:drug effects; D016543:Central Nervous System Neoplasms / Q000188:drug therapy; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D008297:Male; D051379:Mice; D010797:Phthalimides / Q000494:pharmacology*; D012510:Sarcoma 180 / Q000188:drug therapy; D014407:Tumor Cells, Cultured / Q000187:drug effects
D000970:Antineoplastic Agents; C095060:NSC 640168; D010797:Phthalimides